Candidal Esophagitis
Candidal esophagitis (esophageal candidiasis, oesophageal candidiasis) diagnosis information for healthcare professionals. Find clinical documentation and medical coding guidance for Candida esophagitis including ICD-10 codes, SNOMED CT codes, and appropriate terminology for accurate medical records. Learn about symptoms, treatment, and diagnosis of this esophageal infection.
Fungal infection of the esophagus caused by Candida, typically Candida albicans.
Difficulty swallowing (dysphagia), pain with swallowing (odynophagia), retrosternal chest pain, and occasionally nausea or vomiting.
Immunocompromised individuals (HIV/AIDS, transplant recipients), diabetes, antibiotic use, inhaled corticosteroid use.
ICD-10 Code Families
Complete code families applicable to B37.81
When to use each related code
| Description | When to use |
|---|---|
| Yeast infection of the esophagus. | Use for Candida infection specifically affecting the esophagus. Consider symptoms like painful swallowing. |
| Inflammation of the esophagus. | General term for esophageal inflammation. Use when cause is unknown or unspecified. Includes reflux, eosinophilic esophagitis, infections. |
| Viral infection of the esophagus. | Primarily for HSV or CMV infections of the esophagus, often in immunocompromised patients. Consider endoscopic findings. |
Best-practice checklist
- ✓Document endoscopy findings (e.g., white plaques, erythema)
- ✓Record patient symptoms (dysphagia, odynophagia, retrosternal pain)
- ✓Confirm Candida species with lab tests (KOH, culture)
- ✓Note any predisposing factors (immunocompromised, antibiotic use)
- ✓Specify treatment plan (antifungal medication, dosage, duration)
Common pitfalls to avoid
Coding for unspecified candidiasis (B37.9) when clinical documentation supports C. esophagitis (B37.8) leads to lower reimbursement.
Overlooking esophageal involvement when documentation mentions oral or cutaneous candidiasis can impact severity and treatment.
Coding candidal esophagitis without diagnostic confirmation (e.g., endoscopy, culture) may trigger audit scrutiny and denials.
Best-practice tips
- 01ICD-10 B37.8, Candida esophagitis: Confirm with endoscopy + culture.
- 02Rx: Fluconazole, optimize dose/duration per clinical response, document.
- 03CDI: Query for underlying immunocompromised state, impact on PO intake.
- 04Healthcare compliance: Monitor antifungal stewardship, minimize resistance risk.
- 05Esophageal candidiasis: Screen high-risk pts (HIV, transplant) proactively.
Step-by-step checklist
- 1
1. Immunocompromised status? (HIV, transplant, etc.)
- 2
2. Symptoms: Dysphagia, odynophagia, thrush?
- 3
3. Endoscopy with biopsy/culture performed?
- 4
4. Consider differentials: CMV, HSV esophagitis
- 5
5. Document ICD-10 B37.8, SNOMED CT 100785008
Ready-to-paste narrative
Patient presents with complaints consistent with candidal esophagitis, also known as esophageal candidiasis or oesophageal candidiasis. Symptoms include odynophagia, dysphagia, retrosternal chest pain, and heartburn. The patient reports difficulty swallowing both solids and liquids. Oral thrush was noted on examination. The patient's medical history includes recent antibiotic use and a diagnosis of type 2 diabetes mellitus, which are known risk factors for esophageal candidiasis. Differential diagnosis includes gastroesophageal reflux disease (GERD), esophageal spasm, and eosinophilic esophagitis. An esophagogastroduodenoscopy (EGD) with biopsy was performed to confirm the diagnosis. Endoscopic findings revealed white plaques and pseudomembranes consistent with candidal infection. Histopathology confirmed the presence of Candida species. The patient was diagnosed with ICD-10 code B37.81, Candidiasis of esophagus. Treatment plan includes oral fluconazole, with patient education provided on medication management and lifestyle modifications to manage underlying diabetes. Follow-up appointment scheduled in two weeks to assess treatment response and symptom resolution. Prognosis is generally good with appropriate antifungal therapy.
Common questions and answers
What are the most effective diagnostic approaches for differentiating Candidal Esophagitis from other esophageal disorders mimicking its symptoms, such as GERD or eosinophilic esophagitis, in immunocompetent adults?+
Differentiating Candidal Esophagitis from GERD or eosinophilic esophagitis in immunocompetent adults requires a multifaceted approach. While symptoms like dysphagia and odynophagia overlap, endoscopic evaluation with biopsy and histopathological examination for fungal elements is the gold standard for confirming Candidal Esophagitis. In cases where endoscopy is not immediately feasible, a careful review of patient history (e.g., recent antibiotic use, inhaled corticosteroid use), coupled with consideration of a therapeutic trial of fluconazole can aid in the initial assessment. However, a negative response to fluconazole does not definitively rule out Candidal Esophagitis, and endoscopic evaluation remains crucial for definitive diagnosis. Consider implementing a diagnostic algorithm that incorporates both clinical presentation and objective findings to enhance diagnostic accuracy. Explore how combining endoscopic features with histopathology can improve the timely diagnosis of Candidal Esophagitis. Further, serum tests for Candida antibodies aren't routinely recommended due to limited sensitivity and specificity.
Beyond fluconazole, what alternative antifungal treatment strategies are recommended for managing refractory or recurrent Candidal Esophagitis cases in HIV-negative patients, and what are their respective efficacy and safety profiles?+
For refractory or recurrent Candidal Esophagitis in HIV-negative patients unresponsive to fluconazole, several alternative antifungal strategies exist. Itraconazole, in either oral or intravenous formulations, can be effective and generally well-tolerated. Voriconazole, posaconazole, and amphotericin B deoxycholate are typically reserved for more severe or resistant cases due to potential adverse effects, including hepatotoxicity and drug interactions. Echinocandins like caspofungin or micafungin offer another option, particularly for patients with azole resistance. The choice of antifungal agent should be guided by the patient's specific clinical context, including prior treatment response, comorbidities, and potential drug interactions. Learn more about the comparative efficacy and safety profiles of these antifungal agents in managing refractory Candidal Esophagitis. Explore how combination therapy or sequential therapy might enhance treatment outcomes in challenging cases.
How can clinicians effectively manage Candidal Esophagitis in patients with underlying conditions like diabetes mellitus or those receiving immunosuppressive therapy, considering the potential for drug interactions and treatment complications?+
Managing Candidal Esophagitis in patients with diabetes mellitus or those on immunosuppressive therapy necessitates a personalized approach. Optimizing glycemic control in diabetic patients is paramount, as uncontrolled hyperglycemia can exacerbate fungal infections. For immunosuppressed patients, careful consideration of the underlying immunosuppressive regimen is crucial. If feasible, dose reduction or temporary discontinuation of immunosuppressants, in consultation with the specialist managing the underlying condition, might be beneficial. Antifungal choice should account for potential drug interactions with the immunosuppressant medications. Close monitoring for treatment response and adverse events is essential. Consider implementing preventive strategies, such as oral hygiene interventions and prophylactic antifungal therapy, particularly in high-risk individuals. Explore how collaborative management between infectious disease specialists, gastroenterologists, and other relevant specialists can optimize patient outcomes in complex cases of Candidal Esophagitis.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.